Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH Phase 3 losmapimod study in facioscapulohumeral muscular dystrophy
NL-OMON53527Phase 3Recruiting
- Sponsor
- Fulcrum Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of losmapimod, sponsored by Fulcrum Therapeutics. Started Dec 2022; status: recruiting.
02
Drugs
losmapimod
Beyond the preview
Go deeper on NL-OMON53527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53527.